ZSP-1601

N/A

Report date: 2025/09/11 15:45:49
NMEFirst In Class

Base Information

Drug NameZSP-1601
Drug Alias NameZSP-1601ZSYM009ZSYM-009
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 2A inhibitors
TargetsPhosphodiesterase 2A
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangdong Zhongsheng Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangdong Zhongsheng Pharmaceutical Co LtdGuangdong Raynovent Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A